Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

被引：0

作者：

Lonardi, S. ^{[1
]}

Andre, T. ^{[2
,3
]}

Arnold, D. ^{[4
]}

Garcia-Carbonero, R. ^{[5
]}

Chalabi, M. ^{[6
]}

Elez Fernandez, M. E. ^{[7
]}

Lenz, H. J. ^{[8
,9
]}

Jensen, L. H. ^{[10
]}

Joshi, R. ^{[11
]}

Roodhart, J. M. L. ^{[12
]}

Yoshino, T. ^{[13
]}

Dixon, M. ^{[14
]}

Blum, S. I. ^{[15
]}

Sims, J. ^{[16
]}

Lawrance, R. ^{[17
]}

Taylor, F. ^{[18
]}

Chen, T. ^{[19
]}

Cela, E. ^{[20
]}

Jin, L. ^{[21
]}

Van Cutsem, E. ^{[22
,23
]}

机构：

[1] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Padua, Italy

[2] Sorbonne Univ, Med Oncol Dept, Paris, France

[3] Hop St Antoine, Assistance Publ Hop Paris, Paris, France

[4] Asklepios Tumorzentrum AK Altona, Dept Oncol, Hamburg, Germany

[5] UCM, Hosp Univ 12 Octubre Imas12, Dept Med, Madrid, Spain

[6] Netherlands Canc Inst, Dept Gastrointestinal Oncol, Amsterdam, Netherlands

[7] Vall dHebron Univ Hosp & Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain

[8] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Med, Los Angeles, CA USA

[9] Univ Southern Calif, Norris Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA USA

[10] Univ Hosp Southern Denmark, Dept Oncol, Vejle Hosp, Vejle, Denmark

[11] Canc Res SA, Med Oncol, Adelaide, SA, Australia

[12] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands

[13] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Onc, Chiba, Japan

[14] Bristol Myers Squibb, Worldwide Hlth Econ & Outcomes Res, Princeton, NJ USA

[15] Bristol Myers Squibb, Patient Reported Outcome Assessment Asset & Indic, Princeton, NJ USA

[16] Stat Res, Adelphi, Cheshire, England

[17] Adelphi Values, Patient Ctr Outcomes, Adelphi, Cheshire, England

[18] Adelphi Values, Patient Ctr Outcomes, Boston, MA USA

[19] Bristol Myers Squibb, Biostat, Princeton, NJ USA

[20] Bristol Myers Squibb, Oncol Global Drug Dev, Princeton, NJ USA

[21] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA

[22] Univ Hosp Gasthuisberg, Gastroenterol Digest Oncol, Leuven, Belgium

[23] Univ Leuven KU Leuven, Gastroenterol Digest Oncol, Leuven, Belgium

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.013

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S1 / S2

页数：2

共 50 条

[1] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): First results of the CheckMate 8HW study
Andre, Thierry
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Lenz, Heinz-Josef
Manzano Mozo, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Cela, Elvis
Yang, Yingsi
Lei, Ming
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : LBA768 - LBA768
[2] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded efficacy analysis from CheckMate 8HW
Lenz, Heinz-Josef
Lonardi, Sara
Elez, Elena
Van Cutsem, Eric
Jensen, Lars Henrik
Bennouna, Jaafar
Mendez, Guillermo
Schenker, Michael
De La Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Manzano, Jose Luis
Tortora, Giampaolo
Garcia-Carbonero, Rocio
Joshi, Rohit
Cela, Elvis
Chen, Tian
Jin, Lixian
Andre, Thierry
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[3] A phase 3 study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW
Andre, T.
Van Cutsem, E.
Elez, E.
Bennouna, J.
de la Fouchardiere, C.
Yoshino, T.
Jensen, L.
Mendez, G.
Li, J.
Goekkurt, E.
Abdullaev, S.
Chen, T.
Lei, M.
Lonardi, S.
ANNALS OF ONCOLOGY, 2022, 33 : S250 - S250
[4] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Andre, T.
Lonardi, S.
Lenz, H. J.
Jensen, L. H.
Van Cutsem, E.
Touchefeu, Y.
Garcia-Carbonero, R.
Tougeron, D.
Mendez, G. A.
Schenker, M.
de la Fouchardiere, C.
Limon, M. L.
Yoshino, T.
Li, J.
Manzano Mozo, J. L.
Cela, E.
Chen, T.
Lei, M.
Jin, L.
Elez Fernandez, M. E.
ANNALS OF ONCOLOGY, 2024, 35 : S451 - S452
[5] A phase III study of nivolumab (NIVO), NIVO plus ipilimumab (IPI), or chemotherapy (CT) for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): Checkmate 8HW
Abdullaev, Sandzhar
Andre, Thierry
Lei, Ming
Lenz, Heinz-Josef
Novotny, James
Paulson, Andrew Scott
Tejpar, Sabine
Yamazaki, Kentaro
Ledeine, Jean-Marie
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[6] First results of nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) from CheckMate 8HW.
Andre, Thierry
Elez, Elena
Lenz, Heinz-Josef
Jensen, Lars Henrik
Touchefeu, Yann
Van Cutsem, Eric
Garcia-Carbonero, Rocio
Tougeron, David
Mendez, Guillermo
Schenker, Michael
de la Fouchardiere, Christelle
Limon, Maria Luisa
Yoshino, Takayuki
Li, Jin
Aubin, Francine
Cela, Elvis
Chen, Tian
Lei, Ming
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : LBA143 - LBA143
[7] ONCOLOGISTS' PERCEPTIONS OF NIVOLUMAB PLUS IPILUMUMAB (NIVO plus IPI) AS FIRST-LINE (1L) TREATMENT FOR MICROSATELLITE INSTABILITY-HIGH/MISMATCH REPAIR-DEFICIENT (MSI-H/DMMR) METASTATIC COLORECTAL CANCER (MCRC)
Emidio, O.
Iqbal, Z.
Jeune-Smith, Y.
Feinberg, B.
VALUE IN HEALTH, 2024, 27 (12) : S351 - S351
[8] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
Lenz, Heinz-Josef
Overman, Michael J.
Van Cutsem, Eric
Limon, Maria Luisa
Wong, Ka Yeung Mark
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
McCraith, Stephen
Wang, Rui
Lei, Ming
Yao, Jin
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 97 - 97
[9] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142
Lenz, Heinz-Josef
Overman, Michael J.
Van Cutsem, Eric
Limon, M. Luisa
Wong, Mark Ka
Hendlisz, Alain
Aglietta, Massimo
Garcia-Alfonso, Pilar
Neyns, Bart
Gelsomino, Fabio
Cardin, Dana Backlund
Dragovich, Tomislav
Shah, Usman
McCraith, Stephen M.
Wang, Abigail
Lei, Ming
Yao, Jin
Jin, Lixian
Lonardi, Sara
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Quality of life (QoL) in patients (pts) with microsatellite instability (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) alone or in combination with ipilimumab (IPI): CheckMate 142
Van Cutsem, E.
Dixon, M.
Taylor, F.
Sun, X.
Yip, C.
Blum, S. I.
ANNALS OF ONCOLOGY, 2021, 32 : S553 - S553

← 1 2 3 4 5 →